bictegravir

3 · 20 / page

Ask MedXY AI

Latest news

Tag

Infectious Diseasesantiretroviral therapybictegravir

Twice-Daily Bictegravir-Based Therapy Proves Effective and Safe During Rifampicin-Based Tuberculosis Treatment: Insights from the INSIGHT Trial

By MedXY|Jan 14, 2026

The Phase 2b INSIGHT study demonstrates that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) is highly effective and safe for treating HIV in patients receiving rifampicin-based tuberculosis therapy, achieving over 94

Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial

HIV/AIDSbictegravirdolutegravir

bictegravir

Latest news

Twice-Daily Bictegravir-Based Therapy Proves Effective and Safe During Rifampicin-Based Tuberculosis Treatment: Insights from the INSIGHT Trial

Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial